Neose Technologies Inc has entered into an agreement with GlaxoSmithKline, to license certain intellectual property rights of Neose. Under the agreement, GSK has an exclusive license to develop, make and sell certain human vaccines for the prevention, control or treatment of diseases. GSK also has a non-exclusive right to use any other patents owned by Neose that are required to practice its exclusively licensed rights in the same field.
Under the agreement, Neose will receive undisclosed license fees, milestone payments, and royalties on product sales.
Neose is a biopharmaceutical company focused on the improvement of protein therapeutics through the application of its proprietary technologies. By leveraging its GlycoAdvance and GlycoPEGylation technologies, Neose is developing proprietary protein drugs that are improved versions of currently marketed therapeutics with proven efficacy. These next generation proteins are expected to offer significant advantages, such as less frequent dosing and improved safety and efficacy.